TD Cowen analyst Daniel Brennan has maintained their bullish stance on TMO stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Daniel Brennan has given his Buy rating due to a combination of factors that suggest a positive outlook for Thermo Fisher’s stock. The recent second-quarter results exceeded expectations, which was a significant factor in the stock’s favorable reaction. The company showed improvement in biopharma customer growth, marking the strongest performance in ten quarters, and provided optimistic commentary regarding demand and future outlook.
Another reason for the Buy rating is the management’s decision to lower the long-range plan (LRP) and adjust forecasts for 2026 and 2027. This adjustment aligns street estimates with a more realistic growth trajectory, enhancing investor confidence. Brennan believes that the new forecast framework, which anticipates organic growth and potential EPS increases, is reasonable. The company’s leadership position and its significant exposure to consumables and services further support the Buy recommendation, as these factors contribute to a more de-risked financial outlook.
In another report released today, Evercore ISI also maintained a Buy rating on the stock with a $525.00 price target.